TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10952804
Drug: Endoscopic haemostasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic haemostasis using single-modality treatments (injection agents such as epinephrine, sclerosants, thrombogenic substances, or thermal therapies)
Study: 10952804
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy involving injection and thermal techniques
Study: 6375465
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg buprenorphine after bupivacaine
Study: 23023905
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (3 capsules per day: eicosapentaenoic acid 1,548 mg; docosahexaenoic acid 828 mg; other omega-3 fatty acids 338 mg)
Study: 23023905
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (sunflower oil 2,100 mg)
Study: 19778673
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) + Optimal medical therapy (OMT)
Study: 17536129
Drug: Cherries (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cherries (280 g, 4.5 mmol TE AOC)
Study: 9733153
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and DHA ethyl esters (2.04 g EPA and 1.4 g DHA)
Study: 9733153
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (4 g/day)
Study: 2256489
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol (0.035 mg)‐norethindrone (0.40 mg)
Study: 2256489
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol (0.030 to 0.040 mg)‐levonorgestrel (0.050 to 0.125 mg)
Study: 2256489
Drug: non‐oral‐contraceptive group
Approvals — FDA: no, EMA: no, PMDA: no
Description: non‐oral‐contraceptive group
Study: 23522152
Drug: Antibiotic exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic exposure based on clinical presentation of UTI, pyuria, and procalcitonin (PCT) levels.
Study: 9086420
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel and membrane stripping
Study: 9086420
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel and membrane stripping
Study: 9086420
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel and no membrane stripping
Study: 9086420
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel and no membrane stripping
Study: 21672204
Drug: Multivitamin-mineral supplement
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin-mineral supplement
Study: 4057126
Drug: Psychological group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological group treatment aimed at weight reduction, improvement of stress coping, and reduction of salt‐intake, conducted over 16 therapy sessions by trained lay therapists.
Study: 31404055
Drug: Control TDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control TDR (ProDisc-L or Charité)
Study: 22686512
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with adrenaline (40 mL, 2.5 mg/mL bupivacaine and 5 μg/mL adrenaline)
Study: 22686512
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (40 mL, 0.9%)
Study: 20491047
Drug: Topical mydriasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriasis
Study: 16232082
Drug: Isotretinoin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.5 mg/kg per day)
Study: 12090747
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin dalteparin
Study: 10194091
Drug: Testosterone enanthate,
Normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate, 300 mg i.m. every 3 weeks for 6 months
Study: 10194091
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration for 1 year
Study: 7761078
Drug: Methotrexate (7.5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5‐10 mg weekly)
Study: 7761078
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies (im. gold 50 mg weekly or per os steroid max. 10 mg daily)
Study: 27892891
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg loading dose within 18 hours before surgery, followed by 40 mg maintenance dose starting at least 12 hours after surgery for 7 days)
Study: 27892891
Drug: Placebo (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (80 mg loading dose within 18 hours before surgery, followed by placebo maintenance dose)
Study: 21245790
Drug: Sham spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham spinal manipulation therapy (12 treatments over 1 month)
Study: 21245790
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy (12 treatments over 1 month, no maintenance)
Study: 21245790
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy with maintenance (12 treatments over 1 month, maintenance every 2 weeks for 9 months)
Study: 11427783
Drug: Exercise dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise dose
Study: 8183099
Drug: 15N-alanine infusion
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15N-alanine infusion
Study: 30954200
Drug: Unna's boot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unna's boot (compression therapy)
Study: 30954200
Drug: Noncompression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompression therapy (conventional dressing)
Study: 16836503
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg low dose test (LDT)
Study: 16836503
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg standard dose test (SDT)
Study: 10823311
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (3 g/d) and Vitamin E (1500 IU/d) for 8 days
Study: 8900501
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (TA) 4.2 +/- 0.5 mg/kg orally in a single dose
Study: 1710489
Drug: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment
Study: 6512981
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (FOM) administered orally at doses of 50 to 100 mg/kg/day for children and 3 g/day for adults for 5 days.
Study: 6512981
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (FOM) treatment.
Study: 26197776
Drug: 5‐HT₃ receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT₃ receptor antagonist with dexamethasone and aprepitant
Study: 26197776
Drug: 5‐HT₃ receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT₃ receptor antagonist with dexamethasone
Study: 24724983
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg misoprostol sublingually and 20 IU oxytocin intravenously
Study: 24724983
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU of intravenous oxytocin alone
Study: 9731852
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 intracervical gel (Prepidil)
Study: 7994450
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment aiming at a blood pressure < or = 80 mmHg diastolic (group A)
Study: 7994450
Drug: Unchanged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged therapy (group B)
Study: 7994450
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment (group A)
Study: 25012806
Drug: Transcervical 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical 30 mL Foley balloon (FB)
Study: 25012806
Drug: Transcervical 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical 60 mL Foley balloon (FB)
Study: 25012806
Drug: Transcervical 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical 30 mL or 60 mL Foley balloon (FB)
Study: 21996929
Drug: Occupational inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational inhalation exposure to carbon black (CB)
Study: 11021769
Drug: Pivagabine (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivagabine (1800 mg/day for 7 days)
Study: 9167761
Drug: Etoposide at
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide at a dose of 50 mg/d
Study: 9167761
Drug: Etoposide at
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide at a dose of 50 mg/d with G-CSF
Study: 8490006
Drug: Calcium (165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (165 mg Ca as CaCl2) added to a hamburger meal
Study: 8490006
Drug: Calcium (165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (165 mg Ca as CaCl2) added to a wheat roll
Study: 26786573
Drug: 30,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30,000 IU vitamin D3 once weekly for 8 weeks
Study: 17879948
Drug: Intranasal IM862
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal IM862 daily for 6 months or until disease progression.
Study: 17879948
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 6 months or until disease progression.
Study: 9819037
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of recombinant activated factor VII (rFVIIa) targeting a factor VII level of 10 IU/ml
Study: 9819037
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of recombinant activated factor VII (rFVIIa)
Study: 9819037
Drug: Parallel infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parallel infusion of heparin, saline or dextrose‐saline
Study: 1111368
Drug: Morphine-nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine-nitrous oxide anesthesia (2 mg/kg morphine and 70% nitrous oxide in oxygen)
Study: 31775404
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium (PS) 40 mg administered 30 minutes before incision, 12 hours after THA, and every 12 hours for 2 days postoperatively
Study: 19791828
Drug: Saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 2.5 or 5 mg once daily
Study: 19791828
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg once daily plus metformin
Study: 19791828
Drug: Saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 2.5 or 5 mg once daily added to metformin, glyburide, or a thiazolidinedione
Study: 15373926
Drug: Bioadhesive tablet
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive tablet 100 mg
Study: 15373926
Drug: Bioadhesive tablet
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive tablet 50 mg
Study: 15373926
Drug: Oral gel
Normalized name: Oral Gel
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gel (375 mg, 3 times a day)
Study: 11740230
Drug: NaCl therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl therapy (2 mmol/kg/d for 7 days)
Study: 11740230
Drug: NaHCO3 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaHCO3 therapy (2 mmol/kg/d for 7 days)
Study: 9386652
Drug: AC-17 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-17 (300 mg on days 1-2, 150 mg on day 3)
Study: 7970686
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (rest and analgesia)
Study: 18445362
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for 9 weeks
Study: 12515743
Drug: 6-methylprednisolone (6‐MP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylprednisolone (6‐MP; 1 mg/kg BID for 2 days)
Study: 8967668
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (10 micrograms/kg of body weight) for 18 months
Study: 30306325
Drug: Oral piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral piroxicam fast-dissolving tablets
Study: 25773712
Drug: Lixisenatide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 2.5 µg
Study: 25773712
Drug: Lixisenatide 5
Normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 5 µg
Study: 25773712
Drug: Lixisenatide 10
Normalized name: LIXISENATIDE 100MCG/ML INJ,SOLN,PEN,3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 10 µg
Study: 25773712
Drug: Lixisenatide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (all doses)
Study: 25773712
Drug: Lixisenatide (≥5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (≥5 µg)
Study: 19610055
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg once daily
Study: 1656740
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1, followed by 250 mg on days 2-5)
Study: 7047863
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (Deltasone)
Study: 7047863
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (Delta‐cortef)
Study: 7047863
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone (Hydeltrasol)
Study: 7047863
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone and oral prednisolone
Study: 30447165
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene care programme (COHCP): manual toothbrushing with oral hygiene instruction (OHI)
Study: 30447165
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene care programme (AOHCP): powered toothbrushing, mouthrinsing with chlorhexidine and OHI
Study: 24285844
Drug: gD-2 HSV
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gD-2 HSV vaccine adjuvanted with ASO4
Study: 22349765
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g/d for 12 weeks)
Study: 20814825
Drug: Cysteamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine treatment
Study: 16125534
Drug: No-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug
Study: 10573633
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rocuronium (400, 600, 800 micrograms/kg)
Study: 10573633
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rocuronium
Study: 8589028
Drug: Topotecan, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan, administered at 1.5 mg/m2/day IV x 5 days every 3 weeks
Study: 27370359
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal treatment with a long-acting GnRH agonist for 3 months (Group A)
Study: 22739669
Drug: Acidulated phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated phosphate fluoride gel (APF gel, 1.23% F) for 4 min
Study: 22739669
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Er,Cr:YSGG laser and APF gel
Study: 15060257
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine supplementation (CS) 200 mg/kg per day
Study: 9758317
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g every 12 hours
Study: 9758317
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g continuous infusion over 24 hours
Study: 9758317
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g continuous infusion over 24 hours
Study: 9758317
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g continuous infusion plus gentamicin 2 mg/kg
Study: 28746232
Drug: Topical thiocolchicoside
Normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical thiocolchicoside (TCC 0.25%) foam 3 times daily
Study: 28746232
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical thiocolchicoside (No-TCC)
Study: 25894106
Drug: Neurofeedback (NFB)
Normalized name: NFBA
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurofeedback (NFB) plus pharmacotherapy
Study: 23265945
Drug: Four rounds
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four rounds of oral visual inspection by trained health workers at 3-year intervals
Study: 18320411
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) during either one session (3 h) or five sessions (1 h each)
Study: 9010122
Drug: Desipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine treatment (N = 6)
Study: 30798568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with supplemental treatment
Study: 7981429
Drug: MK-679 75
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-679 75 mg
Study: 7981429
Drug: MK-679 250
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-679 250 mg
Study: 7981429
Drug: MK-679 250
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-679 250 mg (oral) + 14C-MK-679 1 mg (IV)
Study: 2595746
Drug: Phenobarbital (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (200 mg)
Study: 29230635
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) substitution
Study: 27647263
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 µg/d Se as Se yeast)
Study: 25017487
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with very low tacrolimus exposure (1.5-3 ng/mL)
Study: 25017487
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with low tacrolimus exposure (4-7 ng/mL)
Study: 18984650
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg sachets, daily from hospital admission until discharge
Study: 18984650
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily from hospital admission until discharge
Study: 18984650
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg sachets
Study: 12842372
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine
Study: 12842372
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A or B vaccines
Study: 8838484
Drug: Desogestrel-containing preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing preparation
Study: 1299421
Drug: alpha‐2a Interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐2a Interferon (IFN) (100,000 I.U. in 1 ml)
Study: 7796587
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 30 mcg ethinylestradiol and 150 mcg desogestrel
Study: 7796587
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 30 mcg ethinylestradiol and 75 mcg gestodene